Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

by Simó, Rafael, Guerci, Bruno, Schernthaner, Guntram, Gallwitz, Baptist, Rosas-Guzmàn, Juan, Dotta, Francesco, Festa, Andreas, Zhou, Ming, Kiljański, Jacek
Published 2015

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries

by Östenson, Claes-Göran, Matthaei, Stephan, Reaney, Matthew, Krarup, Thure, Guerci, Bruno, Kiljanski, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Bruhn, David, Mathieu, Chantal, Theodorakis, Michael
Published 2013

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study

by Matthaei, Stephan, Reaney, Matthew, Mathieu, Chantal, Östenson, Claes-Göran, Krarup, Thure, Guerci, Bruno, Kiljanski, Jacek, Petto, Helmut, Bruhn, David, Theodorakis, Michael
Published 2012

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study

by Reaney, Matthew, Mathieu, Chantal, Östenson, Claes-Göran, Matthaei, Stephan, Krarup, Thure, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Theodorakis, Michael, Guerci, Bruno
Published 2013

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE

by Mathieu, Chantal, Östenson, Claes-Göran, Matthaei, Stephan, Reaney, Matthew, Krarup, Thure, Guerci, Bruno, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Theodorakis, Michael
Published 2013

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study

by Kiiskinen, Urpo, Matthaei, Stephan, Reaney, Matthew, Mathieu, Chantal, Östenson, Claes-Göran, Krarup, Thure, Theodorakis, Michael, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Guerci, Bruno
Published 2013